Medtronic Hugo™ Robotic-Assisted Surgery System Receives European CE Mark Approval

Rhea-AI Summary

Medtronic has announced the receipt of CE Mark for its Hugo™ robotic-assisted surgery system, enabling its sale in Europe for urologic and gynecologic procedures. This approval is significant as robotic surgery currently represents only 3% of global surgeries, despite its benefits like reduced complications and shorter hospital stays. With strong interest from European hospitals, Medtronic plans swift installations, aiming to enhance access to robotic-assisted surgery. The Hugo system emphasizes affordability and utilization, addressing historical barriers to adoption.

Positive

• CE Mark approval for Hugo RAS system expands market potential in Europe.
• Addresses cost and utilization barriers, aiming for higher adoption of robotic surgery.
• Strong interest reported from leading surgical centers in Europe.

Negative

• None.

Multiple Hospitals Across Europe Set to be the First to Install Hugo™ RAS System and Expand the Benefits of Robotic-Assisted Surgery to Their Patients

DUBLIN, Oct. 11, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced it has received CE (Conformité Européenne) Mark for the Hugo™ robotic-assisted surgery (RAS) system, authorizing the sale of the system in Europe. CE Mark approval is for urologic and gynecologic procedures, which make up about half of all robotic procedures performed today.

"This day has been a long time coming, not just for Medtronic, but for the surgeons and hospital leaders who have partnered with us on this journey to bring the benefits of robotic-assisted surgery to more patients around the world. We know our solution is more meaningful because of their insights," said Megan Rosengarten, president of the Surgical Robotics business, which is part of the Medical Surgical Portfolio at Medtronic. "With the Hugo RAS system in our European customers' hands and our dedicated team by their side, together we will redefine what is possible in robotic-assisted surgery."

The Hugo RAS system was designed to address the historic cost and utilization barriers that have stifled robotic surgery adoption for two decades. Globally, about 3% of surgeries are performed robotically,¹ despite offering patients the benefits of minimally invasive surgery — fewer complications, shorter hospital stays, and faster return to normal activities.^2–4,† In Western Europe, about 2% of procedures are done robotically while the majority, approximately 65%, are open surgery.¹ The remainder are traditional minimally invasive surgery.¹

"Robotics and artificial intelligence are the undeniable future of healthcare, with incredible potential to not only advance patient care, but increase access to these benefits," said Rob ten Hoedt, executive vice president and president of the Europe, Middle East, and Africa (EMEA) region at Medtronic. "The Hugo RAS system builds on our leadership in minimally invasive surgery, and we're thrilled to provide hospitals across Europe a robotic-assisted surgery system that is thoughtfully designed to meet their needs today and tomorrow. We've had strong interest from leading surgical centers across Europe and expect to move quickly with multiple installations in several countries."

These hospitals will be the first in Europe to join Medtronic's Partners in Possibility Program, a group of pioneering institutions that will be among the first in the world to use the Hugo RAS system and participate in the global patient registry. Clinicians from these hospitals will participate in hands-on training at Medtronic Surgical Robotics Experience Centers, including two flagship sites operated in partnership with the ORSI Academy in Ghent, Belgium, and IRCAD in Strasbourg, France.

CE Mark approval comes on the heels of major milestones in the Hugo RAS system global launch, including the first urological and gynecological procedures, which took place in Latin America and India and marked the start of the Hugo RAS system global patient registry. A modular, multi-quadrant platform designed for a broad range of surgical procedures, the Hugo RAS system combines wristed instruments, 3D visualization, and a cloud-based surgical video capture option in Touch Surgery™ Enterprise with dedicated support teams specializing in robotics program optimization, service, and training.

The Hugo RAS system is commercially available in certain geographies. Regulatory requirements of individual countries and regions will determine approval, clearance, or market availability. In the EU, the Hugo RAS system is CE marked. In the U.S., the Hugo RAS system is an investigational device not for sale. Touch Surgery Enterprise is not intended to direct surgery, or aid in diagnosis or treatment of a disease or condition.

For more information, visit medtronic.com/hugo.

About Medtronic
Medtronic plc (www.medtronic.com), headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies — alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic employs more than 90,000 people worldwide, serving physicians, hospitals and patients in more than 150 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

†Compared to open surgery.
1.	Based on internal estimates and Medtronic report, FY20 market model: procedural volume data.
2.	Fitch K, Engel T, Bochner A. Cost differences between open and minimally invasive surgery. Managed Care. 2015 Sep;24(9):40–48.
3.	Tiwari MM, Reynoso JF, High R, Tsang AW, Oleynikov D. Safety, efficacy, and cost effectiveness of common laparoscopic procedures. Surg Endosc. 2011;25(4):1127-1135.
4.	Roumm AR, Pizzi L, Goldfarb NI, Cohn H. Minimally invasive: minimally reimbursed? An examination of six laparoscopic surgical procedures. Surg Innov. 2005;12(3):261–287.

 

Contacts:
Gary Jeanfaivre	Ryan Weispfenning
Public Relations	Investor Relations
+1-203-833-2104	+1-763-505-4626

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-hugo-robotic-assisted-surgery-system-receives-european-ce-mark-approval-301396644.html

SOURCE Medtronic plc

FAQ

What is the significance of the CE Mark approval for Medtronic's Hugo system?

The CE Mark approval allows the Hugo robotic-assisted surgery system to be sold in Europe, addressing a significant market with high potential for robotic surgical procedures.

What types of procedures can the Hugo system perform?

The Hugo system is approved for urologic and gynecologic procedures, which account for about half of all robotic surgeries.

How does the adoption rate of robotic surgery impact Medtronic's business?

Robotic surgery only accounts for 3% of global surgeries, indicating substantial room for growth and potential revenue increase for Medtronic with the effective marketing of the Hugo system.

What are the expected outcomes of the installations of the Hugo system in Europe?

Medtronic anticipates redefining robotic-assisted surgery through installations in European hospitals, which could lead to improved patient outcomes and increased surgical efficiency.